(Total Views: 623)
Posted On: 08/16/2020 2:34:38 PM
Post# of 148917
PII/III TRIAL SAYS PLACEBO AND 1 - 1 ENROLLMENT
https://clinicaltrials.gov/ct2/show/NCT043472...amp;rank=4
Official Title: A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
Detailed Description:
This is a Phase 2b/3, two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with severe or critical symptoms of respiratory illness caused by coronavirus 2019 infection.
Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo.
Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.
The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period.
https://clinicaltrials.gov/ct2/show/NCT043472...amp;rank=4
Official Title: A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
Detailed Description:
This is a Phase 2b/3, two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with severe or critical symptoms of respiratory illness caused by coronavirus 2019 infection.
Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo.
Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.
The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period.
(0)
(0)Scroll down for more posts ▼
